PharmAla Biotech Holdings Inc. has publicly filed its financial and operational results for the period ended May 31, 2025, reporting growth in customer deposits and revenue recognition. The company has resumed shipments in Canada and fulfilled U.S. clinical trial sales during Q3. Total expenses for the nine months ended May 31, 2025, increased primarily due to new hires. PharmAla continues to make progress in ensuring a reliable supply of pharmaceutical products for researchers and patients. CEO Nick Kadysh and CFO Will Avery are optimistic about the company’s future prospects in providing MDMA for clinical trials and patient treatments.

Read more at GlobeNewswire: PharmAla Issues Q3 Financial Statements